LATEST NEWS

Piper Jaffray Healthcare Conference

Evercore ISI, HealthconX

Biotech in Europe Forum

STOCK INFORMATION

Marker Therapeutics, Inc.

NSDQ: MRKR

Volume

Day's Range

$

()

Change

52 Week Range

COMPANY OVERVIEW

We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.

LATEST FINANCIAL RESULTS

Q3 2018

Quarterly Results, September 30, 2018      

10-K Book

LATEST 10-K

IR CONTACT DETAILS

Marker Therapeutics, Inc.

Phoenix Tower
3200 Southwest Fwy #2240
Houston, TX 77027
investor.relations@markertherapeutics.com